楚乔传

“药明系”集体上涨！CXO公司集中释放积极信号 机构看好订单回暖持续性_我的网站

一 |     　　在连续两个交易日下挫后，今日创新药行情再度“点火”启动。

二 |     New Delhi, Oct 13 (UNI) Congress leader Shashi Tharoor on Thursday said there were systematic flaws in the Congress presidential election process, even as he clarified he was not suggesting it was intentional.

The Thiruvananthapuram MP also indicated at differential treatment between him and Mallikarjun Kharge, who is being seen as the choice or the party leadership. Congress has maintained the party is not backing any candidate officially.

Addressing a press conference here, Tharoor said while he is not pointing fingers at Central Election Authority Chairman Madhusudan Mistry, there are flaws in the system.

"I am not saying anything against Mr. Mistry, there are some flaws in the systems which we all know. There have not been elections for 22 years..." said Tharoor.

He said there were discrepancies in the lists of voters provided.

"One list was given earlier, another list was given on Wednesday.... Some names were different in the lists, for some names, there was no phone number," he said.

"I am not saying it's being done intentionally. There have not been elections in our party for a long time. So there are issues. I know Mr. Mistry and his team are trying to hold free and fair elections. We are not complaining against them but there ar problems with the system," he said.

"That is why I used open mediums to take my message across. I am not sure I will be able to reach everyone before 17th."

He also pointed at differential treatment to candidates.

"Another issue is what some leaders did, that is why I said there is no level playing field. At a lot of places, big leaders, PCC chiefs welcome Kharge ji, call people for meetings. This happened for only one candidate, not for me," he said.

"Many times when I went to some PCC, the PCC chief became busy on the day...I am not complaining, but do you not see a difference in treatment?"

Election will be held on October 17, counting will be held on October 19 and results will be declared.

UNI AO BAV。截至发稿，凯莱英涨停，益诺思、美迪西涨超8%。“药明系”港股集体上涨，药明康德涨近3%，药明生物涨超7%再创历史新高，药明合联涨超14%。

三 |
　　消息面上，昨夜多家CXO上市公司披露2026年半年度报告。

四 | 从业绩表现来看，企业营收普遍实现稳健增长，盈利水平持续修复。

五 | 　　CRDMO巨头药明合联发布上半年财报：集团营业收入增至 37.01 亿元人民币，按实际汇率计算同比增长37%；归属母公司净利润同比增长 37.4%，至 10.27 亿元人民币；包含潜在里程碑付款，未完成总订单金额约 22 亿美元，同比增长62.2%。　　该公司表示，上述增长主要得益于全球ADC及更广泛的生物偶联药物XDC市场的持续发展，推动客户及项目数量持续增加；客户需求强劲，推动生产设施产能利用率持续维持高位。　　A股方面，科创板两家CRO企业益诺思、美迪西均同比实现扭亏为盈：　　益诺思半年实现营业收入4.65亿元，同比增长23.92%，归母净利润为3917.27万元，上年同期亏损1518.95万元，同比增长357.89%。　　美迪西实现营业收入7.61亿元，同比增长40.91%；实现归母净利润5160.24万元，较去年的同期亏损1289.84万元，同比增长500.07%。　　谈及业绩增长原因，益诺思称系行业需求回暖，带动业务量和订单价格增长所致。美迪西则表示，受益于全球创新药研发需求持续回暖，凭借临床前一体化综合研发平台的竞争优势，公司持续深耕海内外市场，充足订单储备为业绩向好奠定了基础。　　另一CDMO企业凯莱英上半年实现营业收入36.07亿元，同比增长13.13%；实现归母净利润5.2亿元，同比下降15.71%。　　尽管利润增速放缓，其新兴业务服务表现仍可圈可点，报告期内实现收入13.04亿元，同比增长72.49%。其中，化学大分子CDMO业务板块收入7.36亿元，同比增长94.14%。截至本报告披露日，在手订单金额同比增长163.47%，其中境外订单占比68.30%。　　招银国际证券判断，早研需求持续快速增长，已达实质性向上拐点。融资复苏和大药企扩张研发支出稳健支撑全球医药研发生产需求。美国目前利率已显著低于2024-25年，将继续为融资带来边际改善。

六 | 　　该机构强调，全球大药企研发支出加速增长，1H26纳入统计的10家大药企合计研发支出同比增长40.6%，但资本支出相比2025年放缓，或正受控制成本的负面影响，大药企在美巨额投资规划仍未实质性落地。Biotech研发支出延续了2025年的疲弱态势，但继续降低了资本支出，预计将提升对外包研发生产的依赖度。　　华鑫证券指出，中国创新药已逐步从过去的跟随逐步转向原创性的发现，新靶点验证需求提升，带动早研相关产业链的景气度。中邮证券表示，CRO行业已经历一轮中小产能持续出清，集中度提升，项目数量稳步增加的同时价格从前几年下行通道转入逐步复苏。由于签单旺季集中在Q3末至Q4，预计下半年临床CRO板块各业务订单将优于上半年，订单回暖具备持续性。（文章来源：财联社）。

Current article:http://ukf.dangnichuaitongjuanye.pics/news/20260826_6255908.html

Published on:17:08:42